FORMULATION AND EVALUATION OF PRONIOSOMAL GEL-BASED TRANSDERMAL DELIVERY OF ATORVASTATIN CALCIUM BY BOX–BEHNKEN DESIGN

  • SOUJANYA C Department of Pharmaceutics, Vishnu Institute of Pharmaceutical Education and Research, Narsapur, Telangana, India.
  • RAVI PRAKASH P Department of Pharmaceutics, CES College of Pharmacy, Kurnool, Andhra Pradesh, India.

Abstract

Objective: The aim of this study was to investigate the combined influence of three independent variables in the preparation of atorvastatin proniosomes by coacervation-phase separation method.


Methods: On the basis of the preliminary trials, a 3-factor, 3-level Box–Behnken design was employed to study the effect of cholesterol, soya lecithin, and Span 60 independent variable on dependent variables (particle size and % entrapment efficiency). Transmission electron microscopy analysis of optimized formulation has demonstrated the presence of individual proniosomes in spherical shape.


Results: Atorvastatin optimized proniosomal formulation F2 shown better particle size and % entrapment efficiency, and also, the drug release was 99.72% within 24 h in slow and controlled manner when compared with control. Kinetic analysis of drug release profiles showed that the drug release was followed by zero-order manner with Korsmeyer–Peppas model, which implies super case II release kinetics. The particle size and zeta potential of the optimized atorvastatin proniosomal gel were found to be 65.72 and −10.5, respectively. The optimized batch of proniosomes was used for the preparation of atorvastatin-based proniosomal hydrogel by incorporating hydrated proniosomes to carbopol matrix to enhance the stability and viscosity of the system.


Conclusion: The enhanced skin permeation, for a prolonged period of time, may lead to improved efficacy and better patient compliance. This study suggests that proniosomal gel-containing atorvastatin could perform therapeutically better effects than the conventional formulations.

Keywords: Atorvastatin, Proniosomes, Box Behnken Design, Span 60, zeta potential

References

1. Singh S, Trivedi S, Jain S. Design and development of proniosome based transdermal delivery of ondansetron hydrochloride. Int J Pharm Biol Res 2012;3:191-201.
2. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: Dermal and transdermal drug delivery. J Control Release 1994;30:1-15.
3. Aggarwal D, Kaur IP. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm 2005;290:155-9.
4. Wen MM, Farid RM, Kaseem AA. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid. J Liposome Res 2014;24:280-9.
5. Aggarwal G, Dhawan S. Psychotropic drugs and transdermal delivery: An overview. Int J Pharm Bio Sci 2010;1:1-12.
6. Morrow DI, McCarron PA, Woolfson AD, Donnelly RF. Innovative strategies for enhancing topical and transdermal drug delivery. Open Drug Deliv J 2007;1:36-59.
7. Vyas SP, Khar RK. Targeted and Controlled Drug Delivery-Novel Carrier Systems. 1st ed. India: CBS Publishers and Distributors; 2004. p. 249-79.
8. Kaushik D, Mishra PR, Talegaonkar S. Provesicles as surrogate carrier for improved drug delivery. In: Jain NK, editor. Progress in Controlled and Novel Drug Delivery System. India: CBS Publishers and Distributors; 2004. p. 59-274.
9. Alia B, Elnabarawi MA, Elrehem RT, Fayed BA. Formulation and evaluation of dispersed permethrin proniosomes in powder and microemulsion-based hydrogel bases for the treatment of scabies. Int J Pharm Sci 2016;8:221-9.
10. Aacharya A, Kumar GB, Ahmed MG, Paudel S. A novel approach to increase the bioavailability of candesartan cilexetil by proniosomal gel formulation: In-vitro and In-vivo evaluation. Int J Pharm Sci 2016;8:241-6.
11. Florey K. Analytical Profiles of Drug Substances. New York: Academic Press, Inc.;2004. p. 577.
12. Bullen WW, Miller RA, Hayes RN. Development and validation of a high- performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma. J Am Soc Mass Spectrom 1999;10:55-66.
13. Pankaj S, Rini T, Dandagi PM. Formulation and evaluation of proniosome based drug delivery system of antifungal drug clotrimazole. Int J Pharm Sci Nanotech 2013;8:1945-5.
14. Vora B, Khopade AJ, Jain NK. Proniosomes based transdermal delivery of levonorgestrel for effective contraception. J Control Release 1998;54:149-65.
15. Thakur R, Anwer MK, Shams M, Ali A, Khar R.K, Shakeel F, et al. Proniosomal transdermal therapeutic system of losartan potassium: Development and pharmacokinetic evaluation. J Drug Target 2009;17:442-9.
16. Yousuf M, Ahmad M, Usman M, Ketotifen I. Fumarate and salbutamol sulphate combined transdermal patch formulations: In vitro release and ex vivo permeation studies Ali. Ind J Pharm Sci 2013;75:569-77.
17. Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly A. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: In-vitro characterization, skin irritation test and comparative clinical study. Drug Deliv 2015;22:731-9.
18. Jaafari MR, Bavarsad N, Bazzaz BS. Effect of topical liposomes containing paromomycin sulfate in the course of leishmania major infection in susceptible BALB/Mice anti-microbial agents and chemotherapy. Am Soc Microbiol 2009;53:2259-65.
19. Ruan G, Feng SS. Preparation and characterization of poly (lactic acid)- poly (ethylene Glycol)-poly lactic acid (PLA-PEG-PLA) microspheres for the controlled release of paclitaxel. Biomaterials 2003;24:5307-44.
20. Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly A. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: In-vitro characterization, skin irritation test and comparative clinical study. Drug Deliv 2015;22:731-9.
21. El-Maghraby GM, Ahmed AA, Osman MA. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J 2015;23:67-74.
22. Balch DA, Cooke RA. A study of the composition of hen’s egg shell membranes. Ann Biol Anim Biochim Biophys 1970;10:13-25.
23. Yasam VR, Jakki SL, Natarajan J, Kuppusamy G. A review on novel vesicular drug delivery: Proniosomes. Drug Deliv 2014;21:243-9.
24. Akhtar M, Imam SS, Ahmad MA, Najmi AK, Mujeeb M, Aqil M. Neuroprotective study of Nigella sativa-loaded oral provesicular lipid formulation: In-vitro and ex-vivo study. Drug Deliv 2014;21: 487-94.
25. Rahman SA, Abdelmalak NS, Badawi A, Elbayoumy T, Sabry N, El Ramly A. Formulation of tretinoin-loaded topical proniosomes for treatment of acne: In-vitro characterization, skin irritation test and comparative clinical study. Drug Deliv 2015;22:731-9.
26. Ibrahim MM, Sammour OA, Hammad MA, Megrab NA. In-vitro evaluation of proniosomes as a drug carrier for flurbiprofen, AAPS PharmSciTech 2008;9:782-90.
27. Draize JH, Woodard G, Calvery HD. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharm Exp Ther 1944;82:377-90.
Statistics
136 Views | 61 Downloads
How to Cite
SOUJANYA C, and RAVI PRAKASH P. “FORMULATION AND EVALUATION OF PRONIOSOMAL GEL-BASED TRANSDERMAL DELIVERY OF ATORVASTATIN CALCIUM BY BOX–BEHNKEN DESIGN”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 4, Jan. 2019, pp. 335-43, https://innovareacademics.in/journals/index.php/ajpcr/article/view/26707.
Section
Original Article(s)